Please login to the form below

How to innovate and influence people in times of misinformation

The pandemic has shown that public trust in promising new medical technologies is far from a given. Senior Writer Tom Vandyck at StoneArch, a member of Fishawack delves into the right approach to help companies with breakthrough innovations in their pipeline build consumer confidence.

Rewind to late 2019. If you had been told that within a few months, you’d be living in the middle of the biggest pandemic since the 1918 global flu outbreak, but that thanks to new mRNA technology, vaccine prototypes would be ready for trials within weeks and the first shots would go into arms before the end of 2020, what would you have thought?

You could be forgiven for assuming that people would marvel in unison about the miracle of modern medical science. Alas, it didn’t quite go that way.

While most people were relieved to be able to get their shots so soon, a significant section of society went the opposite way and refused to get vaccinated. Some were simply hesitant because they lacked information. A good portion of that group has come around by now. But in the end, the refusal camp was strong enough to hamstring the U.S. vaccination effort, which left us more vulnerable to Delta-driven COVID surges in the summer and fall of 2021, as well as the Omicron variant that showed up toward the end of the year.

Considering what else is in the technology pipeline, that should give us all pause. If the medical sector can’t get a handle on the growing public trust disconnect, it will mean significant dollars lost. But it will also mean that breakthrough innovations will fail to make their full positive impact, which would ultimately create significant adverse public health impacts.

Read the full article on the Stonearch Creative website

11th January 2022



Company Details

Fishawack Health

+44 20 3328 1840

Contact Website

No. 3 Booths Park
Booths Hall
Chelford Road
WA16 8GS
United Kingdom

Latest content on this profile

The challenges of reimbursement and innovative pricing for cell and gene therapies
Our policy and market access experts at Avalere, part of Fishawack Health, share insights on the reimbursement challenges for cell and gene therapies and discuss the challenges and opportunities of innovative pricing models, including ensuring the model chosen meets the payer’s needs.
Fishawack Health
Digital therapeutics as a combination therapy: Maximizing asset value and therapeutic outcomes
Digital therapeutics can increase the value of medicinal assets, driving differentiation and improving outcomes for patients. But are manufacturers prepared to capitalize on this significant untapped opportunity before the tech giants dominate?
Fishawack Health
Fishawack Health welcomes Mario Muredda as its new President of Marketing
Fishawack Health (FH) ushers in a new era of data-driven omnichannel marketing with the hire of healthcare marketing veteran Mario Muredda.
Fishawack Health
5 ways we’re enhancing our services to support our clients in 2023
Fishawack Health CEO Jon Koch explains the new platforms, tools, and services we’re elevating to drive innovation for our clients in 2023.
Fishawack Health
Why it’s time to apply a payer lens to your early pipeline planning
Value, evidence, and market access experts Jan McKendrick and Andrea Hamlin reveal why applying a payer lens early in the value assessment of pipeline assets is essential for driving commercial success.
Fishawack Health
The fast-paced future of cell and gene therapies
In this report, we interview patients, researchers, and biopharmaceutical leaders to explore the complex landscape for the development of cell and gene therapies and share commercial recommendations from our specialist teams.
Fishawack Health